Global vaccines market set for rapid expansion

30 January 2025

The global vaccines market is projected to grow by $194 billion from 2025 to 2029, with an annual growth rate of nearly 23%, according to a report by Technavio.

The expansion is fueled by increased funding for vaccine development and the introduction of new vaccines targeting life-threatening diseases.

The market remains highly fragmented, with key players including AstraZeneca (LSE: AZN), GSK (LSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck KGaA (MRK: DE), Novavax (Nasdaq: NVAX), Pfizer (NYSE: PFE), Sanofi (Euronext: SAN), and Takeda Pharmaceutical (TYO: 4502).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical